RE/MAX (NYSE:RMAX) Misses Q2 CY2026 Sales Expectations

RE/MAX (NYSE:RMAX) reported Q2 CY2026 results that missed Wall Street expectations. Revenue fell 5.8% year on year to $68.51 million, and non-GAAP adjusted EPS was $0.32, down from $0.39 and 18.6% below consensus. Analysts expect revenue to rise 3.3% and full-year EPS to increase from $1.15 to $1.33.

Original reporting
Published Aug 6, 2026, 11:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RE/MAX (NYSE:RMAX) Misses Q2 CY2026 Sales Expectations — source image
Decision brief

The 30-second read

$RMAXBearishMed
01

Why it matters

The key new trading input is the reported Q2 CY2026 revenue decline and adjusted EPS miss, alongside operating margin contraction, which can drive estimate revisions and near-term positioning.

02

Market read

A double miss (revenue and adjusted EPS) with margin compression is a direct catalyst for RE/MAX estimate revisions and sentiment.

03

What to watch

The article does not include management guidance details, balance-sheet changes, or agent productivity trends beyond agent count growth versus revenue, limiting conviction on how quickly margins can recover.

Relevance 7/10Novelty 6/10Timing: post-results, reported Q2 CY2026 miss

Background

RE/MAX is a global real estate franchise operator, and the article frames its Q2 CY2026 performance versus Wall Street expectations.

Company-level read

Ticker impact

$RMAXBearishMedium confidence
Context

RE/MAX reported Q2 CY2026 revenue of $68.51M, down 5.8% YoY, and adjusted EPS of $0.32, missing consensus.

Expected impact

Likely continued pressure on the stock versus peers until management commentary or forward guidance offsets the earnings miss.

Evidence & confidence

The article provides concrete Q2 results versus expectations (revenue and EPS misses) and shows operating margin falling to 2.2% from a year ago, which typically weighs on revisions.

Market effects

Weak franchise demand and monetization signals can pressure sentiment across real estate services/franchise models.

No specific regional catalyst is provided in the article.

RE/MAX operates across 100+ countries, but the article does not identify any geographic driver.

Counterpoint

Analysts expect revenue growth of 3.3% over the next 12 months, suggesting the miss may be a temporary trough rather than a structural decline.

Key entities

  • RE/MAX

    Reported Q2 CY2026 revenue of $68.51M (down 5.8% YoY) and adjusted EPS of $0.32 (below consensus), with operating margin at 2.2%.

Related articles

$RMAXMedAI 8/10

RE/MAX HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS

RE/MAX Holdings (NYSE: RMAX) reported Q2 2026 revenue of $68.5M, down 5.8% year over year, and adjusted EBITDA of $22.9M, down 12.6%. GAAP net loss was $4.3M, or -$0.20 per diluted share. The company also disclosed a planned merger with The Real Brokerage, offering Real REMAX Group shares or $13.80 cash per RMAX share, expected to close in H2 2026.

$RMAXMed

RE/MAX Holdings, Inc. (RMAX): Results of Operations and Financial Condition

RE/MAX Holdings, Inc. (RMAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622438d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RE/MAX HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS Total Second Quarter Revenue of $68.5 Million, Adjusted EBITDA of $22.9 Million DENVER, August 6, 2026 Second Quarter 2026 Highlights (Compared to second quarter 2

$RMAXMedAI 8/10

Why RE/MAX (RMAX) Stock Is Up Today

RE/MAX (RMAX) shares rose after the DOJ granted early termination of the HSR waiting period for its proposed merger with The Real Brokerage, removing a key antitrust review hurdle. The deal still requires shareholder approvals. RMAX closed at $10.71, up 0.9% on the day.

$RMAXMedAI 8/10

Real-REMAX Deal Clears DOJ and FTC Scrutiny

Real’s SEC filing says the DOJ granted early termination of the antitrust waiting period for Real’s $880 million bid to buy RE/MAX. The FTC says early termination occurs only after both agencies complete review and plan no enforcement during the period. Shareholder approval is set for Aug. 14. Real shares rose about 4% after the filing.

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.